Katherine Runyan, PA
Physician Assistant · Knoxville, TNNPI 1164813606
Payments from drug & device makers
Across 1,372 payments — averaging $113.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$53K
- AbbVie$44K
- Pfizer$25K
- UCB, Inc.$15K
- Johnson & Johnson$7K
- Novartis$2K
- plus $10K from 32 others
What the payments were for
- Consulting fees$7,2805%
- Speaking & faculty fees$90,52858%
- Travel & lodging$29,09719%
- Food & beverage$28,24118%
- Education$4280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 304 | $52,554 |
| AbbVie | 347 | $43,972 |
| Pfizer | 82 | $25,160 |
| UCB, Inc. | 100 | $15,491 |
| Johnson & Johnson | 82 | $6,971 |
| Novartis | 111 | $1,908 |
| AstraZeneca(2 entities) | 62 | $1,656 |
| Lilly USA, LLC | 53 | $1,650 |
| Sanofi | 28 | $1,608 |
| GSK | 55 | $955 |
| Mallinckrodt Hospital Products Inc. | 21 | $477 |
| Radius Health, Inc. | 20 | $448 |
| E.r. Squibb & Sons, L.L.C. | 24 | $429 |
| Aurinia Pharma U.S., Inc. | 14 | $422 |
| Boehringer Ingelheim | 12 | $289 |
| Sanofi-aventis U.S. LLC | 2 | $199 |
| Sobi, Inc | 9 | $172 |
| Novo Nordisk | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Sandoz | 5 | $107 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $91 |
| Organon | 5 | $77 |
| Fresenius Kabi USA, LLC | 4 | $77 |
| ANI Pharmaceuticals, Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $36 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Biogen | 1 | $19 |
| Celltrion USA Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,573 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 28 | $301,105 |
| RinvoqUpadacitinib | 34 | $280,082 |
| Cosentyx Unoready PenSecukinumab | 18 | $154,665 |
| EnbrelEtanercept | 19 | $138,112 |
| Enbrel SureclickEtanercept | 14 | $102,030 |
| KevzaraSarilumab | 20 | $87,731 |
| Xeljanz XrTofacitinib Citrate | 11 | $65,532 |
| MethotrexateMethotrexate Sodium | 480 | $12,962 |
| Hydroxychloroquine Sulfate | 336 | $12,589 |
| RasuvoMethotrexate/Pf | 12 | $9,202 |
| Leflunomide | 93 | $6,927 |
| Sulfasalazine DrSulfasalazine | 87 | $4,115 |
| Mycophenolate Mofetil | 28 | $2,929 |
| Prednisone | 262 | $2,277 |
| Sulfasalazine | 44 | $1,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $43,972 | $280,08234 claims |
| AmgenEnbrel | $52,554 | $138,11219 claims |
| SanofiKevzara | $1,608 | $87,73120 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $14 | $94118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Knoxville
- Lindsey NixKnoxville$576K
- Kevin BlazerKnoxville$20K
- Meghan ShotwellKnoxville$18K
- Timothy VanceKnoxville$13K
- Danielle WarrenKnoxville$11K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- John KramerNashville$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.